Clinical Trials

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Carcinoma, Hepatocellular, Neoplasms

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 3 FDA

Carcinoma, Hepatocellular

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Hepatocellular

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05337137 2026-01-12

RELATIVITY-106

83 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Phase 2 Completed

266 enrolled 28 charts

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01658878 2025-12-24

CheckMate040

657 enrolled 57 charts 5 FDA

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT03383458 2025-11-21

CheckMate 9DX

545 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05220722 2025-10-23

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

23 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07219459 2025-10-21

GDFATHERHCC01

104 enrolled

Carcinoma, Hepatocellular

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04943900 2025-04-09

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

GastrointestinalGenitourinaryHead & NeckThoracic

67 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular

NCT02576509 2025-02-17

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 3 Completed

743 enrolled 16 charts

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Hepatocellular

NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Phase 1 Terminated

15 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma

NCT05223816 2024-08-09

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

97 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03418922 2024-06-20

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

30 enrolled 28 charts

Carcinoma, Hepatocellular

NCT02705105 2024-04-25

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

114 enrolled 19 charts

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Unknown

5 enrolled

Carcinoma, Hepatocellular

NCT03893695 2024-02-09

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

20 enrolled

Carcinoma, Hepatocellular

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

93 enrolled 24 charts

CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT03735628 2023-10-06

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

GastrointestinalHead & NeckThoracic

16 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT03829436 2023-07-03

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

52 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03655613 2022-05-06

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

GastrointestinalGenitourinary

20 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT03071094 2021-11-19

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

14 enrolled 13 charts

Carcinoma, Hepatocellular

NCT02859324 2021-05-11

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

21 enrolled 22 charts

Carcinoma, Hepatocellular

NCT02828124 2019-01-30

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

25 enrolled 10 charts